文献速递造血干细胞移植与细胞治疗血栓与止血

补体介导的血栓性微血管病作为内皮损伤与激素难治性移植物抗宿主病之间的关联

Complement-mediated thrombotic microangiopathy as a link between endothelial damage and steroid-refractory GVHD.
PubMed 文献 · Blood Adv · 2018-01-01

该回顾性研究分析了造血干细胞移植后3/4级胃肠道移植物抗宿主病(GVHD)患者的血栓性微血管病(TA-TMA)情况。激素难治性GVHD患者中TA-TMA发生率显著高于激素敏感性GVHD患者(79.3% vs 42.1%;P=0.001)。激素难治性GVHD是TA-TMA发生的危险因素(HR=3.09;95%CI 1.68-5.67;P<0.001)。

要点

  • 激素难治性GVHD患者中TA-TMA发生率79.3%,显著高于激素敏感性GVHD的42.1%(P=0.001)。
  • 激素难治性GVHD是TA-TMA发生的危险因素(HR 3.09;95%CI 1.68-5.67;P<0.001)。
  • GVHD起病后2-6周,合并TA-TMA者BBPlus和C5b-9水平更高,提示替代途径和终末途径激活。

核心结论

  • TA-TMA与造血干细胞移植后总生存期不良相关,可能通过组织学表现早期发现,并可通过测量替代途径和终末补体途径激活与GVHD鉴别。
  • TA-TMA的治疗能否改善激素难治性GVHD患者的生存尚不清楚。

研究设计与样本

  • 回顾性研究,在3/4级胃肠道GVHD患者中识别TA-TMA病例,复习肠道活检标本,并进行TA-TMA相关生物标志物的关联检测。

主要发现

  • 激素难治性GVHD患者中TA-TMA发生率79.3%,激素敏感性GVHD患者中为42.1%(P=0.001)。
  • 在移植后存活100天的患者中,前100天内未发生TA-TMA者自第100天起的1年生存率显著更优(69.5% vs 36.7%;P<0.001)。
  • 7项拟议TA-TMA组织学标准中仅黏膜出血一项在GVHD激素反应组间差异有统计学意义。
  • 多变量模型中,激素难治性GVHD是TA-TMA发生的危险因素(HR 3.09;95%CI 1.68-5.67;P<0.001)。
  • GVHD起病时补体激活无差异;2-6周后,合并TA-TMA者BBPlus中位数600 vs 209.3 ng/mL(P=0.0045),C5b-9中位数425.9 vs 258.4 ng/mL(P=0.029)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Transplant-associated thrombotic microangiopathy (TA-TMA), a complication of hematopoietic cell transplant (HCT), is associated with significant morbidity and mortality. The pathophysiology and overlap of TA-TMA with other posttransplant complications such as graft-versus-host disease (GVHD) is poorly understood. We retrospectively identified cases of TA-TMA among patients with grade 3/4 gastrointestinal (GI) GVHD, reviewed intestinal biopsy specimens, and performed correlative testing of biomarkers associated with TA-TMA. TA-TMA was more common in patients with steroid-refractory GVHD compared with steroid-responsive GVHD (79.3% vs 42.1%; P = .001). Among patients surviving 100 days post-HCT, 1-year survival from day 100 was significantly better for patients who had not developed TA-TMA in the first 100 days (69.5% vs 36.7%; P < .001). Only 1 of 7 proposed TA-TMA histology criteria (mucosal hemorrhage) differed significantly based on GVHD steroid response. In multivariable modeling, steroid-refractory GVHD was a risk factor for development of TA-TMA (hazard ratio, 3.09; 95% confidence interval, 1.68-5.67; P < .001). There were no differences in complement activation at GVHD onset; however, 2 to 6 weeks later, patients with TA-TMA had higher levels of BBPlus and C5b-9, markers of alternative and terminal pathway activation (BBPlus: median, 600 vs 209.3 ng/mL; P = .0045) (C5b-9: median, 425.9 vs 258.4 ng/mL; P = .029). TA-TMA is associated with poor overall survival (OS) following HCT and may be detected early by histologic findings and may be differentiated from GVHD by measurement of alternative and terminal complement pathway activation. It is unknown whether treatment of TA-TMA will improve survival in steroid-refractory GVHD.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Wall SA, Zhao Q, Yearsley M, et al. Complement-mediated thrombotic microangiopathy as a link between endothelial damage and steroid-refractory GVHD. Blood Adv. 2018. PMID: 30327370. doi:10.1182/bloodadvances.2018020321

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。